Regeneron and Sanofi are at it again with their ongoing Dupixent DTC campaign dubbed DU More. The pair of drugmakers rolled out the latest iteration of the campaign on Monday morning, right in time ...

Most people with a condition known as chronic rhinosinusitis with nasal polyps (CRSwNP) are able to control their symptoms by using medicines that are sprayed into the nose or taken by mouth. But some ...

On its way to generating sales of $14 billion in just its seventh full year on the market, Sanofi and Regeneron’s Dupixent has experienced few setbacks. One came in 2023, however, when the FDA ...

Many people with COPD can control their symptoms by using inhaled medicines each day. But inhaled medicines may not offer enough relief for people who also have high levels of a type of white blood ...

The blockbuster Sanofi and Regeneron Pharmaceuticals drug Dupixent, already commercialized in several skin and lung disorders, has expanded its FDA-approval to chronic obstructive pulmonary disease ...

As Sanofi anticipates sales of immunotherapy juggernaut Dupixent reaching a major $22 billion by the end of the decade, fulfilling that goal will hinge on its uptake in chronic obstructive pulmonary ...

Please provide your email address to receive an email when new articles are posted on . The FDA has expanded approval of the single-dose Dupixent pre-filled pen for use in children aged as young as 2 ...